Literature DB >> 9703358

Provirus load in patients with human T-cell leukemia virus type 1 uveitis correlates with precedent Graves' disease and disease activities.

A Ono1, E Ikeda, M Mochizuki, M Matsuoka, K Yamaguchi, T Sawada, S Yamane, S Tokudome, T Watanabe.   

Abstract

We previously demonstrated the increased provirus load in the peripheral blood of patients with human T-cell leukemia virus type 1 (HTLV-1) uveitis (HU). To delineate the relevance of the increased provirus load to clinical and immunologic parameters, we studied the correlation between them. Seventy-nine HU patients (24 male and 55 female) were included in the study, with their informed consent. Plasma samples and genomic DNA of the peripheral blood mononuclear cells were isolated and the provirus load was estimated by semi-quantitative polymerase chain reaction of the gag region sequence. Serum levels of anti-HTLV-1 antibodies and soluble IL-2R were determined by electrochemiluminescence immuno assay and by ELISA, respectively. Disease activities were assessed and graded 0 to 4 according to the evaluation system. Recurrence of the disease during the follow-up period was diagnosed ophthalmologically. The provirus load was significantly higher in the HU patients after Graves' disease (GD) than in those without GD (P<0.05). It correlated with disease activities assessed in terms of vitreous inflammation and interval to recurrence (both P<0.05). In the HU patients without GD, it correlated with the serum levels of soluble IL-2 receptor (P<0.01), and nearly with those of HTLV-1 antibody (P=0.063). These correlations were not found in the HU patients after GD under methimazole treatment. The results suggested a direct involvement of HTLV-1-infected cells in the pathogenesis of uveitis, and raise the possibility that hyperthyroidism may contribute to the clonal expansion of HTLV-1-infected cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703358      PMCID: PMC5921870          DOI: 10.1111/j.1349-7006.1998.tb03262.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  51 in total

1.  trans activation of the tumor necrosis factor alpha promoter by the human T-cell leukemia virus type I Tax1 protein.

Authors:  H Albrecht; A N Shakhov; C V Jongeneel
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

2.  Electrochemiluminescence detection for development of immunoassays and DNA probe assays for clinical diagnostics.

Authors:  G F Blackburn; H P Shah; J H Kenten; J Leland; R A Kamin; J Link; J Peterman; M J Powell; A Shah; D B Talley
Journal:  Clin Chem       Date:  1991-09       Impact factor: 8.327

3.  Correlation between viral DNA load and serum anti p19 antibody concentration in symptomless human T-lymphotropic virus type-I (HTLV-I)-infected individuals.

Authors:  L Morand-Joubert; M Mariotti; D Reed; J C Petit; J J Lefrere
Journal:  Int J Cancer       Date:  1995-01-17       Impact factor: 7.396

4.  The effect of methimazole on the immune system is unlikely to operate directly on T lymphocytes.

Authors:  M Bagnasco; D Venuti; G Ciprandi; G Pesce; F Paolieri; G W Canonica
Journal:  J Endocrinol Invest       Date:  1990-06       Impact factor: 4.256

5.  Immunologic and virologic characterization of the primary infiltrating cells in the aqueous humor of human T-cell leukemia virus type-1 uveitis. Accumulation of the human T-cell leukemia virus type-1-infected cells and constitutive expression of viral and interleukin-6 messenger ribonucleic acids.

Authors:  A Ono; M Mochizuki; K Yamaguchi; N Miyata; T Watanabe
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-03       Impact factor: 4.799

6.  Enhanced expression of LFA-3 on human T-cell lines and leukemic cells carrying human T-cell-leukemia virus type 1.

Authors:  T Imai; Y Tanaka; K Fukudome; S Takagi; K Araki; O Yoshie
Journal:  Int J Cancer       Date:  1993-11-11       Impact factor: 7.396

7.  Spontaneous T cell proliferation and release of soluble interleukin-2 receptors in patients with HTLV-I-associated myelopathy.

Authors:  M Matsumoto; M Sugimoto; H Nakashima; F Imamura; O Kawano; E Uyama; K Takatsu; S Araki
Journal:  Am J Trop Med Hyg       Date:  1990-04       Impact factor: 2.345

8.  Clinical and immunologic features of human T-cell lymphotropic virus type I uveitis.

Authors:  K Yoshimura; M Mochizuki; S Araki; N Miyata; K Yamaguchi; K Tajima; T Watanabe
Journal:  Am J Ophthalmol       Date:  1993-08-15       Impact factor: 5.258

9.  Prevalence of serum and salivary antibodies to HTLV-1 in Sjögren's syndrome.

Authors:  K Terada; S Katamine; K Eguchi; R Moriuchi; M Kita; H Shimada; I Yamashita; K Iwata; Y Tsuji; S Nagataki
Journal:  Lancet       Date:  1994-10-22       Impact factor: 79.321

10.  Frequent clonal proliferation of human T-cell leukemia virus type 1 (HTLV-1)-infected T cells in HTLV-1-associated myelopathy (HAM-TSP).

Authors:  Y Furukawa; J Fujisawa; M Osame; M Toita; S Sonoda; R Kubota; S Ijichi; M Yoshida
Journal:  Blood       Date:  1992-08-15       Impact factor: 22.113

View more
  10 in total

1.  HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years.

Authors:  T Matsuzaki; M Nakagawa; M Nagai; K Usuku; I Higuchi; K Arimura; H Kubota; S Izumo; S Akiba; M Osame
Journal:  J Neurovirol       Date:  2001-06       Impact factor: 2.643

2.  Long-term follow-up of HTLV-1 proviral load in asymptomatic carriers and in incident cases of HAM/TSP: what is its relevance as a prognostic marker for neurologic disease?

Authors:  Marina Lobato Martins; Jacqueline Cronemberger Guimarães; João Gabriel Ribas; Luiz Cláudio Ferreira Romanelli; Anna Bárbara de Freitas Carneiro-Proietti
Journal:  J Neurovirol       Date:  2016-09-27       Impact factor: 2.643

3.  Predictive markers for development of strongyloidiasis in patients infected with both Strongyloides stercoralis and HTLV-1.

Authors:  M Satoh; S Kiyuna; Y Shiroma; H Toma; A Kokaze; Y Sato
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

4.  Identification of dysregulated pathways underlying HTLV-1-associated myelopathy/tropical spastic paraparesis through co-expression network analysis.

Authors:  Mohadeseh Zarei Ghobadi; Sayed-Hamidreza Mozhgani; Yousef Erfani
Journal:  J Neurovirol       Date:  2021-01-06       Impact factor: 2.643

5.  Increased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue disease.

Authors:  Maria Yakova; Agnès Lézin; Fabienne Dantin; Gisèle Lagathu; Stéphane Olindo; Georges Jean-Baptiste; Serge Arfi; Raymond Césaire
Journal:  Retrovirology       Date:  2005-02-01       Impact factor: 4.602

6.  Point-of-Care System for HTLV-1 Proviral Load Quantification by Digital Mediator Displacement LAMP.

Authors:  Lisa Becherer; Jacob Friedrich Hess; Sieghard Frischmann; Mohammed Bakheit; Hans Nitschko; Silvina Stinco; Friedrich Zitz; Hannes Hofer; Giampiero Porro; Florian Hausladen; Karl Stock; Dominik Drossart; Holger Wurm; Hanna Kuhn; Dominik Huber; Tobias Hutzenlaub; Nils Paust; Mark Keller; Oliver Strohmeier; Simon Wadle; Nadine Borst; Roland Zengerle; Felix von Stetten
Journal:  Micromachines (Basel)       Date:  2021-02-05       Impact factor: 2.891

7.  HTLV-1 uveitis.

Authors:  Koju Kamoi; Manabu Mochizuki
Journal:  Front Microbiol       Date:  2012-07-24       Impact factor: 5.640

Review 8.  Viruses and thyroiditis: an update.

Authors:  Rachel Desailloud; Didier Hober
Journal:  Virol J       Date:  2009-01-12       Impact factor: 4.099

9.  Human T-lymphotropic virus type 1 (HTLV-1) prevalence and quantitative detection of DNA proviral load in individuals with indeterminate/positive serological results.

Authors:  Francesca Vitone; Davide Gibellini; Pasqua Schiavone; Antonietta D'Antuono; Lorenzo Gianni; Isabella Bon; Maria Carla Re
Journal:  BMC Infect Dis       Date:  2006-03-02       Impact factor: 3.090

Review 10.  Role of Viral Infections in the Pathogenesis of Sjögren's Syndrome: Different Characteristics of Epstein-Barr Virus and HTLV-1.

Authors:  Hideki Nakamura; Toshimasa Shimizu; Atsushi Kawakami
Journal:  J Clin Med       Date:  2020-05-13       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.